2.30pm – 3.15pm BST, 21 April 2026 ‐ 45 mins
Session
Companies deploying biosolutions have the potential to change the world across multiple sectors. A harmonised, transparent and accessible regulatory environment is necessary not only to ensure responsible innovation of these disruptive biotechnologies, but also to protect UK biosolutions companies from uncertainty in their development pipelines, investor nervousness and global market volatility.
In this session we will explore how the UK can foster a globally attractive culture of responsible BioSolutions innovation – enabling companies to innovate rapidly and at scale, while reducing biosecurity risks, maintaining public trust, and supporting a stable operating environment attractive to investors.




Responsible Innovation Lead Engineering Biology, DSIT



Engineering Biology Partnerships Lead, National Physical Laboratory
Jeffrey Anthony joined NPL in 2019 and works as part of NPL’s Life Sciences & Health Partnerships Team. With a focus on the building collaborations across the Life science sector Jeffrey works with collaborators across industry, academic and public sector to identify the ways in which NPL’s metrology expertise and capability can help to support research and its translation to drive growth.
Jeffrey’s technical background is in microbiology, and he has worked in roles across quality assurance, and both product and business development. His experience includes the pharmaceutical sector, the development of genomic marker technologies in agritech and activities in cell biology. In his current role his time is dedicated to building partnerships across the UK and internationally across standards and metrology in Engineering Biology supporting companies in their quest to scale and commercialise at pace.

Technology Development Lead, Croda
Sarah has several years’ experience working in the chemicals industry, and in that time has become a specialist on sustainable chemistry. In her day job, Sarah indulges her passions for science and sustainability, through her role as Technology Development Lead at Croda. In this role she coordinates Croda’s external collaborations, building a vast external network. She has also had a leading role in developing Croda’s first ever Net Zero roadmaps. Prior to this, she has had various roles in Croda in R&D and Corporate Sustainability, following the completion of her Master’s in Chemistry with Industrial Experience from the University of Sheffield. She sits on the Biobased Biodegradable Industry Association board, the University of Bath’s Institute for Sustainability and Climate Change.
Co-Founder & COO, CDotBio
Dr Veronica Greco is Co-founder and COO of CDotBio, developing a universal delivery platform to improve efficacy and reduce product use across agricultural inputs. She leads commercial operations, market strategy, and IP, shaping how CDotBio’s technology is positioned, structured, and deployed within real market and regulatory environments, and aligning development with clear pathways to adoption.
With a PhD in Synthetic Biology and a background in pharmaceutical chemistry, she works at the interface of science, commercialisation, and regulatory environments. Her work centres on translating scientific innovation into scalable, economically viable solutions that can be adopted by industry and attract investment.

VP, Product and Marketing , Ribbon Bio
Divya is a biotechnology leader with over a decade of experience in product and commercial strategy, managing global portfolios for both established companies and startups. She has held impactful roles at QIAGEN, Automata, and Congenica, leading cross-functional teams and driving growth for multi-million-dollar portfolios across automation, reagents, and software. Divya holds a B.S. in Microbiology, Zoology, and Chemistry from Mount Carmel College, Bangalore, and an M.S. in Communication Science from North Carolina State University, positioning her at the nexus of biotech innovation and product development.
Partner, SeaX Ventures
Jo is a Partner at SeaX Ventures, where he leads investments in early-stage companies shaping the future of deep tech, healthtech, and climate. With over 14 years of experience across venture capital, private equity, and special situations, he brings a cross-disciplinary perspective on scaling breakthrough technologies globally.
Prior to joining SeaX Ventures, Jo was part of the investment teams at Ares Management (NYSE: ARES), PROPARCO, Lakeshore Capital, and Bangkok Bank, with experience spanning distressed investing, impact investing, growth equity, and buyouts.
He holds an MBA from the University of Oxford and is both a CFA® charterholder and a certified Financial Risk Manager (FRM®).